I figure $9.50 this week. Probably in the $8 range prior to the 2ndQ release and most likely a blood bath after that. I can't see an up side at all and especially after they are turned down by the FDA to loosen up on the REMS and a very poor quarterly report.
Smells like you guys are becoming quite concerned about your short position. The calender through July is beginning to tighten around your necks like a noose isn't it? Do you still think there are shareholders on this board that will sell you there shares? The next 3 months and to the end of the year for that matter is why institutions and retail investors went long with Vivus. The seas are getting quite choppy for anyone short.